Form 4 for NVCR NovoCure Ltd
Accepted 2022-12-05 00:00:00 ET · period of report 2022-12-02 · accession 0001645113-22-000096 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-12-05 | 2022-12-02 | NVCR | Cordova Ashley | CFO | M - OptEx | $7.15 | +2,000 | 74.4K | +3% | +$14.3K |
| D | 2022-12-05 | 2022-12-02 | NVCR | Cordova Ashley | CFO | M - OptEx | $7.15 | -2,000 | 7,752 | -21% | -$14.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2022-12-02 | M | A | 2,000 | $7.15 | 74,376 | D | — | — | |
| 2 | Derivative | Options to Buy Ordinary Shares | 2022-12-02 | M | D | 2,000 | $7.15 | 7,752 | D | $7.15 · — to 2027-02-21 | 2,000 Ordinary Shares | (F1) Fully vested as of the date hereof. |